Migdal Insurance & Financial Holdings Ltd. maintained its stake in Kamada Ltd. (NASDAQ:KMDA) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 463,434 shares of the biotechnology company’s stock at the close of the second quarter. Migdal Insurance & Financial Holdings Ltd. owned approximately 1.27% of Kamada worth $2,781,000 as of its most recent SEC filing.
A number of other large investors also recently made changes to their positions in the business. Nexthera Capital LP purchased a new position in Kamada during the second quarter valued at $1,805,000. Vanguard Group Inc. raised its stake in shares of Kamada by 6.5% in the second quarter. Vanguard Group Inc. now owns 468,390 shares of the biotechnology company’s stock worth $2,810,000 after purchasing an additional 28,382 shares during the last quarter. Edmond DE Rothschild Holding S.A. raised its stake in shares of Kamada by 10.5% in the second quarter. Edmond DE Rothschild Holding S.A. now owns 42,200 shares of the biotechnology company’s stock worth $251,000 after purchasing an additional 4,000 shares during the last quarter. Finally, Renaissance Technologies LLC raised its stake in shares of Kamada by 16.7% in the first quarter. Renaissance Technologies LLC now owns 264,800 shares of the biotechnology company’s stock worth $1,801,000 after purchasing an additional 37,800 shares during the last quarter. Institutional investors and hedge funds own 7.29% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://transcriptdaily.com/2017/10/08/migdal-insurance-financial-holdings-ltd-has-2781000-holdings-in-kamada-ltd-kmda.html.
Kamada Ltd. (NASDAQ:KMDA) traded down 0.52% on Friday, hitting $4.75. The stock had a trading volume of 20,393 shares. The firm’s market cap is $177.65 million. The company has a 50-day moving average price of $4.60 and a 200 day moving average price of $6.00. Kamada Ltd. has a 52-week low of $3.75 and a 52-week high of $8.61.
Kamada (NASDAQ:KMDA) last issued its quarterly earnings data on Tuesday, August 1st. The biotechnology company reported $0.13 EPS for the quarter, beating the consensus estimate of $0.12 by $0.01. Kamada had a negative return on equity of 2.94% and a negative net margin of 2.24%. The firm had revenue of $32.55 million during the quarter, compared to analyst estimates of $33.30 million. During the same quarter in the prior year, the business posted ($0.04) EPS. The business’s revenue for the quarter was up 70.7% compared to the same quarter last year. Equities analysts forecast that Kamada Ltd. will post $0.09 earnings per share for the current fiscal year.
KMDA has been the subject of several recent analyst reports. Zacks Investment Research cut Kamada from a “hold” rating to a “sell” rating in a research note on Tuesday, July 18th. TheStreet cut Kamada from a “c-” rating to a “d+” rating in a research note on Tuesday, August 1st. Jefferies Group LLC restated a “buy” rating and issued a $7.00 price target (down previously from $9.00) on shares of Kamada in a research note on Wednesday, August 2nd. Finally, ValuEngine cut Kamada from a “hold” rating to a “sell” rating in a research note on Friday, September 1st. Two analysts have rated the stock with a sell rating and two have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $8.50.
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
Want to see what other hedge funds are holding KMDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kamada Ltd. (NASDAQ:KMDA).
Receive News & Ratings for Kamada Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.